Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been...

Descripción completa

Detalles Bibliográficos
Autores principales: Vélez-Santamaría, Valentina, Nedkova, Velina, Díez, Laura, Homedes, Christian, Alberti, M. Antonia, Casasnovas, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331764/
https://www.ncbi.nlm.nih.gov/pubmed/32655688
http://dx.doi.org/10.1177/1756286420932035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331764/
https://www.ncbi.nlm.nih.gov/pubmed/32655688
http://dx.doi.org/10.1177/1756286420932035

Ejemplares similares